Biostatistics, GlaxoSmithKline, Brentford, UK.
Biostatistics, GlaxoSmithKline, Stevenage, UK.
Pharm Stat. 2021 Nov;20(6):1102-1111. doi: 10.1002/pst.2128. Epub 2021 May 7.
In this paper, we extend the use of assurance for a single study to explore how meeting a study's pre-defined success criteria could update our beliefs about the true treatment effect and impact the assurance of subsequent studies. This concept of conditional assurance, the assurance of a subsequent study conditional on success in an initial study, can be used assess the de-risking potential of the study requiring immediate investment, to ensure it provides value within the overall development plan. If the planned study does not discharge sufficient later phase risk, alternative designs and/or success criteria should be explored. By transparently laying out the different design options and the risks associated, this allows for decision makers to make quantitative investment choices based on their risk tolerance levels and potential return on investment. This paper lays out the derivation of conditional assurance, discusses how changing the design of a planned study will impact the conditional assurance of a future study, as well as presenting a simple illustrative example of how this methodology could be used to transparently compare development plans to aid decision making within an organisation.
在本文中,我们将单一研究的保证范围进行扩展,探索如何满足研究预先设定的成功标准可以更新我们对真实治疗效果的信念,并影响后续研究的保证。这种有条件保证的概念,即后续研究对初始研究成功的保证,可以用于评估需要立即投资的研究的风险降低潜力,以确保其在整体开发计划中具有价值。如果计划的研究不能释放足够的后期阶段风险,则应探索替代设计和/或成功标准。通过透明地列出不同的设计选项和相关风险,这允许决策者根据其风险承受能力水平和潜在投资回报进行定量投资选择。本文阐述了条件保证的推导过程,讨论了改变计划研究的设计将如何影响未来研究的条件保证,并通过一个简单的示例说明了如何使用这种方法来透明地比较开发计划,以帮助组织内的决策。